| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.451 | 0.043 | 0.784 | Toll-Like receptor 7 agonist | 0.355 0.079 DBMET03502 0.784 0.005 DBMET03503 0.568 0.021 DBMET03504 | DBMET03503 | |
| 0.445 | 0.045 | 0.779 | Toll-Like receptor agonist | 0.349 0.083 DBMET03502 0.779 0.005 DBMET03503 0.561 0.022 DBMET03504 | DBMET03503 | |
| 0.139 | 0.024 | 0.143 | Potassium channel activator | 0.143 0.022 DBMET03503 0.088 0.064 DBMET03504 | DBMET03503 | |
| 0.123 | 0.046 | 0.139 | Chemokine receptor antagonist | 0.139 0.037 DBMET03502 0.099 0.063 DBMET03503 | DBMET03502 | |
| 0.083 | 0.012 | 0.083 | Purinergic P2X antagonist | 0.069 0.018 DBMET03502 0.067 0.019 DBMET03503 0.055 0.027 DBMET03504 | ||
| 0.101 | 0.032 | 0.101 | 3C-Like protease (SARS coronavirus) inhibitor | 0.091 0.044 DBMET03502 | ||
| 0.093 | 0.024 | 0.093 | Purinergic P2 antagonist | 0.075 0.035 DBMET03502 0.071 0.039 DBMET03503 | ||
| 0.065 | 0.009 | 0.065 | Purinergic P2X7 antagonist | 0.045 0.017 DBMET03502 | ||
| 0.066 | 0.018 | 0.09 | Glutamate (mGluR group I) agonist | 0.07 0.016 DBMET03502 0.09 0.01 DBMET03503 0.073 0.015 DBMET03504 | DBMET03503 | |
| 0.081 | 0.035 | 0.081 | Secretase beta inhibitor | |||
| 0.062 | 0.017 | 0.072 | Glutamate (mGluR5) agonist | 0.061 0.017 DBMET03502 0.072 0.013 DBMET03503 0.059 0.019 DBMET03504 | DBMET03503 | |
| 0.064 | 0.02 | 0.074 | Glutamate (mGluR5) antagonist | 0.074 0.015 DBMET03502 0.045 0.035 DBMET03503 | DBMET03502 | |
| 0.057 | 0.014 | 0.075 | Factor XIa inhibitor | 0.075 0.009 DBMET03502 | DBMET03502 | |
| 0.065 | 0.029 | 0.065 | Ca(v)3.2 blocker | |||
| 0.197 | 0.162 | 0.197 | Nootropic | |||
| 0.229 | 0.203 | 0.63 | Analgesic | 0.544 0.038 DBMET03503 0.63 0.022 DBMET03504 | DBMET03504 | |
| 0.048 | 0.026 | 0.048 | Baculoviral IAP repeat-containing protein inhibitor | |||
| 0.076 | 0.056 | 0.086 | CC chemokine receptor antagonist | 0.086 0.046 DBMET03502 | DBMET03502 | |
| 0.052 | 0.033 | 0.052 | Antiviral (Hepatitis D) | 0.051 0.035 DBMET03502 | ||
| 0.036 | 0.02 | 0.037 | Factor XI inhibitor | 0.037 0.02 DBMET03502 | DBMET03502 | |
| 0.067 | 0.053 | 0.086 | Glutamate (mGluR group I) antagonist | 0.086 0.033 DBMET03502 0.068 0.051 DBMET03503 0.063 0.06 DBMET03504 | DBMET03502 | |
| 0.031 | 0.025 | 0.034 | GHS receptor antagonist | 0.034 0.019 DBMET03503 0.03 0.028 DBMET03504 | DBMET03503 | |
| 0.119 | 0.113 | 0.251 | Anticoagulant | 0.163 0.07 DBMET03502 0.251 0.038 DBMET03503 | DBMET03503 | |
| 0.026 | 0.029 | 0.031 | Potassium channel subfamily K member 3 blocker | 0.028 0.025 DBMET03502 0.031 0.02 DBMET03503 | DBMET03503 | |
| 0.051 | 0.055 | 0.198 | Glutamate (mGluR) agonist | 0.198 0.009 DBMET03503 0.194 0.01 DBMET03504 | DBMET03503 | |
| 0.02 | 0.039 | 0.029 | Vasopressin 1 antagonist | 0.029 0.026 DBMET03502 | DBMET03502 | |
| 0.057 | 0.08 | 0.408 | Glutamate receptor agonist | 0.408 0.004 DBMET03503 0.174 0.014 DBMET03504 | DBMET03503 | |
| 0.058 | 0.081 | 0.084 | Glutamate (mGluR) antagonist | 0.084 0.046 DBMET03502 0.083 0.046 DBMET03503 0.081 0.049 DBMET03504 | DBMET03502 | |
| 0.021 | 0.051 | 0.033 | Antidiuretic hormone antagonist | 0.033 0.032 DBMET03502 | DBMET03502 | |
| 0.022 | 0.059 | 0.174 | Factor VIIa inhibitor | 0.049 0.02 DBMET03502 0.174 0.006 DBMET03503 | DBMET03503 | |
| 0.046 | 0.106 | 0.068 | Nav1.8 sodium channel blocker | 0.068 0.058 DBMET03503 | DBMET03503 | |
| 0.033 | 0.099 | 0.044 | Parathyroid hormone antagonist | 0.044 0.033 DBMET03503 | DBMET03503 | |
| 0.062 | 0.143 | 0.091 | Polo-like kinase-1 inhibitor | 0.091 0.06 DBMET03503 | DBMET03503 | |
| 0.026 | 0.119 | 0.048 | Guanylate cyclase stimulant | 0.048 0.023 DBMET03503 0.042 0.034 DBMET03504 | DBMET03503 | |
| 0.212 | 0.316 | 0.441 | Antiinflammatory | 0.28 0.234 DBMET03503 0.441 0.115 DBMET03504 | DBMET03504 | |
| 0.011 | 0.119 | 0.019 | Potassium channel (Inward rectifier) 11 blocker | 0.019 0.011 DBMET03503 | DBMET03503 | |
| 0.034 | 0.144 | 0.095 | CXC chemokine receptor antagonist | 0.095 0.027 DBMET03503 | DBMET03503 | |
| 0.066 | 0.185 | 0.139 | Sodium channel blocker | 0.139 0.066 DBMET03503 | DBMET03503 | |
| 0.081 | 0.201 | 0.181 | TRKC antagonist | 0.181 0.078 DBMET03503 | DBMET03503 | |
| 0.078 | 0.208 | 0.103 | Interleukin 2 antagonist | 0.103 0.082 DBMET03503 | DBMET03503 | |
| 0.053 | 0.19 | 0.285 | Glutamate receptor antagonist | 0.285 0.011 DBMET03503 0.163 0.042 DBMET03504 | DBMET03503 | |
| 0.065 | 0.216 | 0.134 | CDK3/cyclin E inhibitor | 0.134 0.04 DBMET03503 0.101 0.086 DBMET03504 | DBMET03503 | |
| 0.074 | 0.235 | 0.143 | Aurora-C kinase inhibitor | 0.143 0.06 DBMET03503 0.134 0.075 DBMET03504 | DBMET03503 | |
| 0.101 | 0.264 | 0.144 | CC chemokine 6 receptor antagonist | 0.144 0.031 DBMET03503 | DBMET03503 | |
| 0.078 | 0.294 | 0.174 | MAP kinase 3 inhibitor | 0.158 0.056 DBMET03503 0.174 0.039 DBMET03504 | DBMET03504 | |
| 0.026 | 0.242 | 0.047 | Sodium/calcium exchanger inhibitor | 0.047 0.042 DBMET03503 | DBMET03503 | |
| 0.007 | 0.283 | 0.028 | MAP3K8 inhibitor | 0.028 0.023 DBMET03503 | DBMET03503 | |
| 0.097 | 0.375 | 0.223 | Antiobesity | 0.223 0.183 DBMET03503 | DBMET03503 | |
| 0.003 | 0.29 | 0.021 | Complement factor D inhibitor | 0.021 0.008 DBMET03503 | DBMET03503 | |
| 0.006 | 0.314 | 0.033 | AMPA receptor agonist | 0.032 0.031 DBMET03503 0.033 0.029 DBMET03504 | DBMET03504 | |
| 0.02 | 0.334 | 0.101 | CXC chemokine 1 receptor antagonist | 0.101 0.005 DBMET03503 | DBMET03503 | |
| 0.005 | 0.321 | 0.032 | Glutamate (mGluR2) agonist | 0.031 0.023 DBMET03503 0.032 0.023 DBMET03504 | DBMET03504 | |
| 0.008 | 0.332 | 0.042 | Glutamate (mGluR group II) agonist | 0.038 0.021 DBMET03503 0.042 0.019 DBMET03504 | DBMET03504 | |
| 0.009 | 0.337 | 0.032 | Purinergic P2X3 antagonist | 0.032 0.029 DBMET03504 | DBMET03504 | |
| 0.014 | 0.352 | 0.045 | Potassium channel Kv1.1 blocker | 0.045 0.016 DBMET03503 | DBMET03503 | |
| 0.004 | 0.393 | 0.036 | Aggrecanase 2 inhibitor | 0.036 0.008 DBMET03504 | DBMET03504 | |
| 0.004 | 0.411 | 0.025 | Diacylglycerol O-acyltransferase 1 inhibitor | 0.025 0.024 DBMET03503 | DBMET03503 | |
| 0.024 | 0.434 | 0.145 | Protein kinase (CK1) gamma 1 inhibitor | 0.145 0.073 DBMET03503 | DBMET03503 | |
| 0.03 | 0.459 | 0.189 | Cell wall synthesis inhibitor | 0.117 0.104 DBMET03503 0.189 0.035 DBMET03504 | DBMET03504 | |
| 0.086 | 0.516 | 0.365 | Cyclophilin D inhibitor | 0.365 0.112 DBMET03503 | DBMET03503 | |
| 0.014 | 0.45 | 0.107 | Protein kinase (CK1) gamma inhibitor | 0.107 0.106 DBMET03503 | DBMET03503 | |
| 0.012 | 0.472 | 0.169 | Aggrecanase 1 inhibitor | 0.169 0.004 DBMET03504 | DBMET03504 | |
| 0.033 | 0.497 | 0.091 | Glutamate (mGluR7) agonist | 0.091 0.082 DBMET03503 | DBMET03503 | |
| 0.003 | 0.48 | 0.037 | CXC chemokine 2 receptor antagonist | 0.037 0.009 DBMET03503 | DBMET03503 | |
| 0.007 | 0.517 | 0.042 | Dihydroorotase inhibitor | 0.042 0.035 DBMET03503 | DBMET03503 | |
| 0.01 | 0.53 | 0.175 | Glutamate (mGluR group III) agonist | 0.175 0.004 DBMET03503 0.141 0.005 DBMET03504 | DBMET03503 | |
| 0.077 | 0.613 | 0.36 | Interleukin 2 agonist | 0.36 0.041 DBMET03503 0.339 0.05 DBMET03504 | DBMET03503 | |
| 0.013 | 0.556 | 0.075 | Cell adhesion molecule inhibitor | 0.075 0.06 DBMET03503 | DBMET03503 | |
| 0.006 | 0.575 | 0.055 | Integrin alpha2 antagonist | 0.055 0.009 DBMET03503 0.042 0.018 DBMET03504 | DBMET03503 | |
| 0.007 | 0.59 | 0.063 | Aryl hydrocarbon receptor antagonist | 0.063 0.049 DBMET03503 | DBMET03503 | |
| 0.019 | 0.612 | 0.119 | Cell adhesion inhibitor | 0.119 0.066 DBMET03503 0.102 0.086 DBMET03504 | DBMET03503 | |
| 0.001 | 0.606 | 0.039 | NMDA receptor glycine site antagonist | 0.039 0.009 DBMET03503 | DBMET03503 | |
| 0.003 | 0.61 | 0.026 | Kainate receptor 4 antagonist | 0.026 0.016 DBMET03504 | DBMET03504 | |
| 0.022 | 0.632 | 0.171 | Lanosterol 14 alpha demethylase inhibitor | 0.147 0.013 DBMET03503 0.171 0.007 DBMET03504 | DBMET03504 | |
| 0.003 | 0.619 | 0.022 | Kainate receptor 5 antagonist | 0.022 0.014 DBMET03504 | DBMET03504 | |
| 0.006 | 0.649 | 0.065 | HIV-1 integrase inhibitor | 0.065 0.055 DBMET03504 | DBMET03504 | |
| 0.006 | 0.649 | 0.065 | Sphingosine 1-phosphate receptor 3 antagonist | 0.065 0.032 DBMET03503 | DBMET03503 | |
| 0.006 | 0.672 | 0.057 | Tryptophan 5 hydroxylase inhibitor | 0.057 0.004 DBMET03503 0.035 0.028 DBMET03504 | DBMET03503 | |
| 0.007 | 0.678 | 0.065 | Potassium channel intermediate-conductance Ca-activated blocker | 0.065 0.033 DBMET03504 | DBMET03504 | |
| 0.002 | 0.704 | 0.063 | Phosphorylase inhibitor | 0.063 0.023 DBMET03503 | DBMET03503 | |
| 0.007 | 0.711 | 0.067 | Botulinum neurotoxin type A inhibitor | 0.067 0.029 DBMET03503 0.061 0.036 DBMET03504 | DBMET03503 | |
| 0.006 | 0.714 | 0.12 | Sphingosine 1-phosphate receptor antagonist | 0.12 0.013 DBMET03503 | DBMET03503 | |
| 0.004 | 0.713 | 0.035 | Integrin alpha2beta1 antagonist | 0.035 0.008 DBMET03503 0.027 0.017 DBMET03504 | DBMET03503 | |
| 0.054 | 0.771 | 0.242 | Nitric-oxide synthase stimulant | 0.242 0.038 DBMET03503 0.234 0.045 DBMET03504 | DBMET03503 | |
| 0.01 | 0.743 | 0.053 | Glutamate (mGluR8) antagonist | 0.051 0.008 DBMET03503 0.053 0.007 DBMET03504 | DBMET03504 | |
| 0.005 | 0.738 | 0.063 | Sphingosine 1-phosphate receptor 1 antagonist | 0.063 0.025 DBMET03503 | DBMET03503 | |
| 0.002 | 0.747 | 0.043 | Glucagon receptor antagonist | 0.043 0.012 DBMET03503 | DBMET03503 | |
| 0.003 | 0.764 | 0.082 | Glutamate (mGluR4) agonist | 0.082 0.005 DBMET03503 0.064 0.008 DBMET03504 | DBMET03503 | |
| 0.002 | 0.771 | 0.088 | Glutamate (mGluR3) antagonist | 0.077 0.005 DBMET03503 0.088 0.005 DBMET03504 | DBMET03504 | |
| 0.004 | 0.781 | 0.071 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.071 0.058 DBMET03504 | DBMET03504 | |
| 0.015 | 0.792 | 0.178 | ATPase inhibitor | 0.167 0.075 DBMET03503 0.178 0.061 DBMET03504 | DBMET03504 | |
| 0.001 | 0.783 | 0.029 | Methionyl aminopeptidase 1 inhibitor | 0.029 0.027 DBMET03504 | DBMET03504 | |
| 0.002 | 0.785 | 0.062 | Prostaglandin-E synthase inhibitor | 0.062 0.06 DBMET03503 | DBMET03503 | |
| 0.017 | 0.81 | 0.135 | Tumour necrosis factor antagonist | 0.135 0.119 DBMET03503 | DBMET03503 | |
| 0.052 | 0.845 | 0.265 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.265 0.264 DBMET03503 | DBMET03503 | |
| 0.009 | 0.81 | 0.147 | Sphingosine 1-phosphate receptor 5 antagonist | 0.147 0.066 DBMET03503 | DBMET03503 | |
| 0.013 | 0.847 | 0.08 | D-Ala-D-Ala ligase inhibitor | 0.08 0.068 DBMET03503 | DBMET03503 | |
| 0.001 | 0.837 | 0.049 | Kainate receptor 2 antagonist | 0.034 0.027 DBMET03503 0.049 0.017 DBMET03504 | DBMET03504 | |
| 0.001 | 0.851 | 0.023 | Glutamate (mGluR1a) agonist | 0.023 0.014 DBMET03503 | DBMET03503 | |
| 0.005 | 0.866 | 0.052 | Glutamate (mGluR4) antagonist | 0.052 0.019 DBMET03504 | DBMET03504 | |
| 0.002 | 0.863 | 0.05 | Thymidylate synthase inhibitor | 0.05 0.028 DBMET03503 | DBMET03503 | |
| 0.001 | 0.862 | 0.046 | Kainate receptor antagonist | 0.046 0.024 DBMET03504 | DBMET03504 | |
| 0.006 | 0.869 | 0.709 | Tumour necrosis factor alpha release inhibitor | 0.709 0.005 DBMET03504 | DBMET03504 | |
| 0.001 | 0.874 | 0.038 | Kynurenine 3 monooxygenase inhibitor | 0.038 0.01 DBMET03503 0.029 0.016 DBMET03504 | DBMET03503 | |
| 0.007 | 0.889 | 0.114 | Interleukin 8 antagonist | 0.114 0.07 DBMET03503 | DBMET03503 | |
| 0.002 | 0.886 | 0.117 | NMDA receptor antagonist | 0.117 0.037 DBMET03503 | DBMET03503 | |
| 0.008 | 0.892 | 0.092 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.092 0.063 DBMET03503 | DBMET03503 | |
| 0.011 | 0.911 | 0.201 | RNA-directed DNA polymerase inhibitor | 0.201 0.098 DBMET03503 | DBMET03503 | |
| 0.003 | 0.906 | 0.147 | Ferrochelatase inhibitor | 0.147 0.039 DBMET03503 0.102 0.069 DBMET03504 | DBMET03503 | |
| 0.003 | 0.909 | 0.116 | Sphingosine 1-phosphate receptor 2 antagonist | 0.116 0.107 DBMET03503 | DBMET03503 | |
| 0.004 | 0.912 | 0.098 | DOPA decarboxylase inhibitor | 0.098 0.079 DBMET03503 0.096 0.084 DBMET03504 | DBMET03503 | |
| 0.026 | 0.938 | 0.275 | 5 Hydroxytryptamine uptake stimulant | 0.275 0.06 DBMET03503 0.236 0.096 DBMET03504 | DBMET03503 | |
| 0.001 | 0.915 | 0.113 | NMDA receptor glycine site agonist | 0.113 0.011 DBMET03503 0.091 0.021 DBMET03504 | DBMET03503 | |
| 0.003 | 0.92 | 0.04 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.04 0.033 DBMET03504 | DBMET03504 | |
| 0.002 | 0.926 | 0.046 | Glutamate (mGluR group III) antagonist | 0.046 0.026 DBMET03504 | DBMET03504 | |
| 0.003 | 0.93 | 0.103 | Alpha-N-acetylglucosaminidase inhibitor | 0.103 0.097 DBMET03503 | DBMET03503 | |
| 0.004 | 0.932 | 0.2 | Non-steroidal antiinflammatory agent | 0.2 0.071 DBMET03504 | DBMET03504 | |
| 0.01 | 0.939 | 0.27 | 5 Hydroxytryptamine release inhibitor | 0.27 0.201 DBMET03503 | DBMET03503 | |
| 0.002 | 0.934 | 0.091 | Cystathionine beta-synthase inhibitor | 0.091 0.088 DBMET03503 | DBMET03503 | |
| 0.003 | 0.948 | 0.073 | Glutamate (mGluR6) antagonist | 0.069 0.041 DBMET03503 0.073 0.034 DBMET03504 | DBMET03504 | |
| 0.002 | 0.948 | 0.114 | NMDA receptor agonist | 0.114 0.015 DBMET03503 0.081 0.028 DBMET03504 | DBMET03503 | |
| 0.004 | 0.954 | 0.231 | 5-Lipoxygenase inhibitor | 0.231 0.019 DBMET03504 | DBMET03504 | |
| 0.002 | 0.958 | 0.155 | Succinate dehydrogenase inhibitor | 0.155 0.104 DBMET03503 0.146 0.121 DBMET03504 | DBMET03503 | |
| 0.004 | 0.96 | 0.285 | Cholesterol antagonist | 0.269 0.112 DBMET03503 0.285 0.101 DBMET03504 | DBMET03504 | |
| 0.002 | 0.959 | 0.204 | Lipoxygenase inhibitor | 0.204 0.136 DBMET03504 | DBMET03504 | |
| 0.002 | 0.959 | 0.086 | GABA C receptor agonist | 0.086 0.084 DBMET03503 | DBMET03503 | |
| 0.004 | 0.966 | 0.113 | Leukotriene synthesis inhibitor | 0.113 0.019 DBMET03504 | DBMET03504 | |
| 0.008 | 0.976 | 0.187 | Tyrosine 3 hydroxylase inhibitor | 0.187 0.16 DBMET03504 | DBMET03504 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |